JP2010529026A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529026A5
JP2010529026A5 JP2010510385A JP2010510385A JP2010529026A5 JP 2010529026 A5 JP2010529026 A5 JP 2010529026A5 JP 2010510385 A JP2010510385 A JP 2010510385A JP 2010510385 A JP2010510385 A JP 2010510385A JP 2010529026 A5 JP2010529026 A5 JP 2010529026A5
Authority
JP
Japan
Prior art keywords
composition
booster
human
peptide
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010510385A
Other languages
English (en)
Japanese (ja)
Other versions
JP5635399B2 (ja
JP2010529026A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/060044 external-priority patent/WO2008150577A1/en
Publication of JP2010529026A publication Critical patent/JP2010529026A/ja
Publication of JP2010529026A5 publication Critical patent/JP2010529026A5/ja
Application granted granted Critical
Publication of JP5635399B2 publication Critical patent/JP5635399B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010510385A 2007-06-01 2008-04-11 乳癌再発の予防のためのワクチン Expired - Fee Related JP5635399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94152407P 2007-06-01 2007-06-01
US60/941,524 2007-06-01
PCT/US2008/060044 WO2008150577A1 (en) 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014138567A Division JP6097724B2 (ja) 2007-06-01 2014-07-04 乳癌再発の予防のためのワクチン

Publications (3)

Publication Number Publication Date
JP2010529026A JP2010529026A (ja) 2010-08-26
JP2010529026A5 true JP2010529026A5 (enExample) 2011-04-28
JP5635399B2 JP5635399B2 (ja) 2014-12-03

Family

ID=40094045

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2010510385A Expired - Fee Related JP5635399B2 (ja) 2007-06-01 2008-04-11 乳癌再発の予防のためのワクチン
JP2014138567A Expired - Fee Related JP6097724B2 (ja) 2007-06-01 2014-07-04 乳癌再発の予防のためのワクチン
JP2016211150A Pending JP2017071607A (ja) 2007-06-01 2016-10-28 乳癌再発の予防のためのワクチン
JP2018153050A Expired - Fee Related JP7072467B2 (ja) 2007-06-01 2018-08-16 乳癌再発の予防のためのワクチン
JP2020161232A Pending JP2021001218A (ja) 2007-06-01 2020-09-25 乳癌再発の予防のためのワクチン
JP2022068170A Pending JP2022095926A (ja) 2007-06-01 2022-04-18 乳癌再発の予防のためのワクチン

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014138567A Expired - Fee Related JP6097724B2 (ja) 2007-06-01 2014-07-04 乳癌再発の予防のためのワクチン
JP2016211150A Pending JP2017071607A (ja) 2007-06-01 2016-10-28 乳癌再発の予防のためのワクチン
JP2018153050A Expired - Fee Related JP7072467B2 (ja) 2007-06-01 2018-08-16 乳癌再発の予防のためのワクチン
JP2020161232A Pending JP2021001218A (ja) 2007-06-01 2020-09-25 乳癌再発の予防のためのワクチン
JP2022068170A Pending JP2022095926A (ja) 2007-06-01 2022-04-18 乳癌再発の予防のためのワクチン

Country Status (16)

Country Link
US (6) US8222214B2 (enExample)
EP (2) EP2162149B1 (enExample)
JP (6) JP5635399B2 (enExample)
KR (5) KR101572474B1 (enExample)
CN (2) CN105816867A (enExample)
AU (1) AU2008260399C1 (enExample)
CA (1) CA2687368C (enExample)
CY (1) CY1114912T1 (enExample)
DK (1) DK2162149T3 (enExample)
ES (1) ES2445399T3 (enExample)
HR (1) HRP20140102T1 (enExample)
MX (1) MX2009012858A (enExample)
PL (1) PL2162149T3 (enExample)
PT (1) PT2162149E (enExample)
SI (1) SI2162149T1 (enExample)
WO (1) WO2008150577A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP2162149B1 (en) 2007-06-01 2013-11-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
CA2744035C (en) 2008-12-10 2018-07-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer recurrence
EP2814836B1 (en) 2012-02-17 2017-11-08 Mayo Foundation For Medical Education And Research Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide
US10028918B2 (en) 2012-05-08 2018-07-24 Albert Einstein College Of Medicine, Inc. Nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine and uses thereof
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
CA2840997A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961700A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
US20160258951A1 (en) * 2013-10-28 2016-09-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of monitoring immune responses
WO2015127027A1 (en) * 2014-02-20 2015-08-27 Wayne State University Her2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
ES2986360T3 (es) 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1
WO2017210255A1 (en) 2016-05-31 2017-12-07 Galena Biopharma, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
MA53933A (fr) 2018-10-21 2021-08-25 Slsg Ltd Llc Poly-immunothérapie pour le traitement du cancer du sein triple-négatif
KR20240006547A (ko) 2021-05-04 2024-01-15 주식회사 애스톤사이언스 Her2 백신 조성물
KR20230017640A (ko) 2021-07-28 2023-02-06 주식회사 애스톤사이언스 Her2 백신 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
EP0474727B1 (en) 1989-05-19 1997-07-23 Genentech, Inc. Her2 extracellular domain
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
AU712441B2 (en) 1994-12-14 1999-11-04 Scripps Research Institute, The In vivo activation of tumor-specific cytotoxic T cells
US6514942B1 (en) 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US20030022820A1 (en) 1995-12-14 2003-01-30 Linda A. Sherman In vivo activation of tumor-specific cytotoxic t cells
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US7060284B1 (en) * 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20030224036A1 (en) 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
US20070098776A1 (en) 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
AU2002318186A1 (en) * 2001-07-03 2003-01-21 Lexicon Genetics Incorporated Novel human kielin-like proteins and polynucleotides encoding the same
JP2005514326A (ja) 2001-07-10 2005-05-19 コリクサ コーポレイション ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
US20030049253A1 (en) 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
EP1482963A4 (en) 2002-03-08 2010-06-09 Univ Texas CONTROLLED MODULATION OF THE AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGEN
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
CA2499837C (en) * 2002-10-03 2013-12-03 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
EP1597276A4 (en) * 2003-02-10 2006-11-29 Autogen Res Pty Ltd Therapeutic molecules
AU2004289170B2 (en) 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005014634A1 (en) 2003-08-12 2005-02-17 Agt Biosciences Limited A gene and uses therefor
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
US20060275777A1 (en) 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
EP2162149B1 (en) * 2007-06-01 2013-11-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse

Similar Documents

Publication Publication Date Title
HRP20140102T1 (hr) Cjepivo za prevenciju relapsa raka dojke
Wallach et al. Advances in the treatment of neuromyelitis optica spectrum disorder
RU2435782C2 (ru) Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
JP2014114288A5 (enExample)
Melo et al. Golimumab (anti-TNF monoclonal antibody): where we stand today
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
JP2016530323A5 (enExample)
JP2012102122A5 (enExample)
CN108392633A (zh) Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用
US9884098B2 (en) Multivalent breast cancer vaccine
JP2024001125A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2015517511A5 (enExample)
JP2014500278A5 (enExample)
JP2015526446A5 (enExample)
JP2017503810A5 (enExample)
AU2025202861A1 (en) Vaccine compositions and methods for restoring NKG2D pathway function against cancers
JP2021514003A5 (enExample)
JP2014500278A (ja) 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与
Lee et al. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination
JP2023536655A5 (enExample)
JP2018522041A (ja) 改変酵母−ブラキュリー免疫療法組成物
CN103768595A (zh) 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗
JP2009544610A5 (enExample)
US20200000899A1 (en) Pharmaceutical composition for use in the treatment of cancer
JP2015516980A5 (enExample)